HK1202429A1 - Methods for prevention and treatment of acute renal injury - Google Patents

Methods for prevention and treatment of acute renal injury Download PDF

Info

Publication number
HK1202429A1
HK1202429A1 HK15102987.4A HK15102987A HK1202429A1 HK 1202429 A1 HK1202429 A1 HK 1202429A1 HK 15102987 A HK15102987 A HK 15102987A HK 1202429 A1 HK1202429 A1 HK 1202429A1
Authority
HK
Hong Kong
Prior art keywords
group
renal
aromatic
subject
kidney
Prior art date
Application number
HK15102987.4A
Other languages
English (en)
Chinese (zh)
Inventor
Hazel H. Szeto
Diane Felsen
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of HK1202429A1 publication Critical patent/HK1202429A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15102987.4A 2008-02-26 2015-03-24 Methods for prevention and treatment of acute renal injury HK1202429A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3158508P 2008-02-26 2008-02-26
US61/031585 2008-02-26

Publications (1)

Publication Number Publication Date
HK1202429A1 true HK1202429A1 (en) 2015-10-02

Family

ID=41013650

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102987.4A HK1202429A1 (en) 2008-02-26 2015-03-24 Methods for prevention and treatment of acute renal injury

Country Status (7)

Country Link
US (9) US8143219B2 (enExample)
EP (3) EP3243521B1 (enExample)
JP (5) JP5677096B2 (enExample)
CN (4) CN106975070A (enExample)
DK (1) DK2262520T3 (enExample)
HK (1) HK1202429A1 (enExample)
WO (1) WO2009108695A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
AU2006292352B2 (en) 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US8143219B2 (en) * 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011025734A1 (en) 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
US20110082084A1 (en) * 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
CA3008993A1 (en) * 2010-01-25 2011-07-28 Cornell University Aromatic-cationic peptides and uses of same
US8585597B2 (en) * 2010-03-12 2013-11-19 Sonogenix, Inc. Renal injury inhibiting devices, systems, and methods employing low-frequency ultrasound or other cyclical pressure energies
EP3040080A1 (en) * 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2566880A4 (en) * 2010-05-03 2014-10-08 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
JP2014502510A (ja) * 2010-12-31 2014-02-03 ゼウス サイエンティフィック、インク． 分子核酸ベースの技術を使用している細胞生存度を決定する改良された方法
WO2012129427A2 (en) * 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
WO2012158518A1 (en) * 2011-05-13 2012-11-22 The Penn State Research Foundation Treatment of renal injury
BR112014003118A2 (pt) * 2011-08-10 2017-03-14 Digna Biotech Sl composto que induz atividade de cardiotrofina-1 (ct-1) para uso na prevenção e/ou tratamento de lesão renal aguda, composição e uso de uma composição
CN103987397A (zh) * 2011-09-29 2014-08-13 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CA2852454A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
US9353171B2 (en) 2011-11-17 2016-05-31 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
EP2788013A4 (en) 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3281634A1 (en) * 2012-02-22 2018-02-14 Stealth Peptides International, Inc. Method and compositions for preventing or treating ophthalmic conditions
JP2015509504A (ja) 2012-02-23 2015-03-30 コーネル ユニヴァーシティー 芳香族陽イオン性ペプチドおよびその使用
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
EP4005582A1 (en) * 2012-10-22 2022-06-01 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
JP6518197B2 (ja) * 2013-03-01 2019-05-22 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
CN116474071A (zh) * 2013-03-01 2023-07-25 康德生物医疗有限公司 治疗线粒体疾病的方法
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9895410B2 (en) 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
US10905818B2 (en) * 2014-03-31 2021-02-02 Zoll Medical Corporation Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome
SI3160984T1 (sl) 2014-06-25 2021-08-31 Flamma S.P.A. Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
US10112976B2 (en) 2014-06-30 2018-10-30 Flamma S.P.A. Process for the production of D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
CA2958585C (en) 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
JP6946342B2 (ja) * 2016-05-09 2021-10-06 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ エバンスブルー誘導体の化学的コンジュゲート、ならびに放射線治療剤およびイメージング剤としてのそれらの使用
CN107644976B (zh) * 2016-07-22 2020-09-29 清华大学 锂离子电池电极
US11123345B2 (en) 2016-11-21 2021-09-21 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
EP3692032B1 (en) 2017-10-03 2024-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
IL276653B2 (en) 2018-02-22 2024-11-01 Us Health Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
WO2020018381A1 (en) * 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
CN109946139A (zh) * 2019-02-28 2019-06-28 东南大学 一种石蜡切片免疫组化套染pas试剂盒及其染色方法和应用
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
WO2020214518A1 (en) * 2019-04-18 2020-10-22 Arcuate Therapeutics, Inc. Methods of treating renal conditions using peptides that improve mitochondrial function
CN110250110A (zh) * 2019-07-11 2019-09-20 南京医科大学附属逸夫医院 一种顺铂所致急性肾损伤的小鼠模型的构建方法
EP3771467A1 (en) * 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN113209294B (zh) * 2020-02-05 2023-06-13 复旦大学 Dor激动剂在制备对抗肾脏纤维化药物中的应用
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
KR102308991B1 (ko) 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CA3172610A1 (en) * 2020-04-08 2021-10-14 Soo Jin Lee Agent for treating contrast-induced acute kidney injury
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
GB2614162B (en) 2020-09-09 2024-11-06 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
US20220079984A1 (en) * 2020-09-11 2022-03-17 Renibus Therapeutics, Inc. Method for treating cancer with kidney protection
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ATE136905T1 (de) 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
WO1994028012A1 (en) * 1993-05-28 1994-12-08 Warner-Lambert Company Hydroxamate inhibitors of endothelin converting enzyme
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7856600A (en) 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
DK1263464T3 (da) 2000-03-09 2013-01-28 Genzyme Corp Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion
ATE496533T1 (de) 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
WO2002083106A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
AU2006292352B2 (en) * 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury

Also Published As

Publication number Publication date
US11628198B2 (en) 2023-04-18
EP3243521B1 (en) 2020-05-27
WO2009108695A3 (en) 2009-12-30
JP2011513241A (ja) 2011-04-28
WO2009108695A2 (en) 2009-09-03
JP2016175924A (ja) 2016-10-06
US20230398172A1 (en) 2023-12-14
US8143219B2 (en) 2012-03-27
US20130017150A1 (en) 2013-01-17
US20190388492A1 (en) 2019-12-26
US20210023161A1 (en) 2021-01-28
JP5677096B2 (ja) 2015-02-25
EP2262520A2 (en) 2010-12-22
JP2017226697A (ja) 2017-12-28
US20180177840A1 (en) 2018-06-28
EP3243521A1 (en) 2017-11-15
HK1246673A1 (en) 2018-09-14
US20170112893A1 (en) 2017-04-27
CN101951936A (zh) 2011-01-19
DK2262520T3 (en) 2017-08-07
JP2019059785A (ja) 2019-04-18
CN107802821A (zh) 2018-03-16
EP2262520A4 (en) 2012-02-29
US20090221514A1 (en) 2009-09-03
JP2015063561A (ja) 2015-04-09
US20140107033A1 (en) 2014-04-17
US20150353602A1 (en) 2015-12-10
US8940696B2 (en) 2015-01-27
CN104056248A (zh) 2014-09-24
EP3741381B1 (en) 2024-04-24
EP2262520B1 (en) 2017-05-03
EP3741381A1 (en) 2020-11-25
CN106975070A (zh) 2017-07-25
US8592373B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
US20230398172A1 (en) Methods for prevention and treatment of acute renal injury
JP6319738B2 (ja) 虚血／再灌流障害に続くノーリフローの予防又は処置方法
CN106913860A (zh) 芳族阳离子肽和使用它们的方法
EP3459598A1 (en) Combinations of peptide therapeutics and methods for using same
JP2014522879A (ja) 腎疾患の治療のためのカルジオトロフィン−１の使用
HK1235712A1 (en) Methods for prevention and treatment of acute renal injury
HK1246673B (en) A peptide for use for prevention and treatment of acute renal injury
Huang et al. Sequential-Targeting Nanomedicine Protects Against Acute Kidney Injury by Modulating Calcium Influx and Scavenging Reactive Oxygen Species
Henderson et al. MP060 EXISTENCE OF THE AUTOREACTIVE T CELLS FOUND IN GOODPASTURE’S DISEASE IS ACCOUNTABLE BY PROPERTIES OF ENDOSOMAL PROCESSING
US20080194491A1 (en) Methods of Diagnosing, Preventing, and Treating Early Onset of Pulmonary Hypertension